Quick answer : Ketamine has shown rapid antidepressant effects in studies of bipolar depression, but treatment requires careful psychiatric evaluation because bipolar depression is different from unipolar major depression. Most IV ketamine studies in bipolar depression have used ketamine in addition to mood-stabilizing treatment, and the available evidence is smaller than the evidence base for unipolar treatment-resistant depression. The possibility of hypomania or mania also requires clinical attention.
Bipolar disorder includes episodes of depression as well as periods of mania or hypomania. Depressive episodes can look remarkably similar to major depressive disorder. Symptoms may include low mood, fatigue, anhedonia, impaired concentration, sleep changes, hopelessness, and suicidal thoughts.
This overlap creates an important diagnostic challenge. Someone may seek treatment during a depressive episode without recognizing earlier periods of mood elevation as clinically significant.
The distinction matters because bipolar depression and unipolar depression require different treatment strategies.
Researchers have studied ketamine in people with bipolar depression, although the evidence remains much smaller than the evidence for major depressive disorder.
A 2021 systematic review identified six experimental studies involving 135 participants. All six studies used IV ketamine alongside a mood-stabilizing medication. The review found preliminary evidence of antidepressant benefit but also emphasized the need for additional research.
An updated 2023 systematic review included eight studies with 235 participants. It again found evidence of antidepressant effects while highlighting the limited amount of available data. The researchers also called for better studies on repeated and maintenance treatment.
The findings are encouraging, but clinicians should not treat bipolar depression as simply another form of major depression.
Clinicians should ask people seeking treatment for depression about previous periods of unusually elevated or irritable mood. They should also ask about increased energy, decreased need for sleep, racing thoughts, rapid speech, impulsivity, increased goal-directed activity, and behavior that differed significantly from the person’s usual baseline.
A history of becoming unusually activated after taking an antidepressant can also provide important clinical information. Family history may offer additional clues.
None of these features alone establishes a diagnosis of bipolar disorder. However, they can signal the need for a more detailed psychiatric evaluation before treatment begins.
Researchers have reported hypomanic or manic symptoms during ketamine treatment. However, the available studies remain too small to define the risk precisely.
In the 2023 systematic review of bipolar depression, six participants across the pooled studies developed hypomanic or manic symptoms after treatment. Five of those participants had received ketamine.
These findings do not mean ketamine commonly causes mania. They do highlight mood elevation as an important clinical consideration, particularly for someone with known or suspected bipolar disorder.
Published IV ketamine studies in bipolar depression have generally examined ketamine alongside ongoing mood-stabilizing treatment. Researchers have not generally studied ketamine as a replacement for mood stabilizers.
Medication decisions should always be individualized. Patients should not stop lithium, anticonvulsants, antipsychotics, or other psychiatric medications simply because they plan to begin ketamine treatment. The clinicians managing those medications should guide any changes.
Coordination between the ketamine clinician and the patient’s psychiatric prescriber can play an especially important role in bipolar disorder.
When someone has not responded to several antidepressants, it is natural to focus on finding a stronger treatment. Sometimes, however, the more important step involves making sure the diagnostic framework is correct.
Bipolar depression, trauma-related disorders, substance-related symptoms, sleep disorders, ADHD, and some medical conditions can overlap with symptoms commonly attributed to major depression.
A broader reassessment does not mean the previous diagnosis was necessarily wrong. Instead, it gives clinicians an opportunity to take another look at persistent or treatment-resistant symptoms before adding more treatment.
Ketamine may have a role in selected patients with bipolar depression. Systematic reviews have found promising antidepressant effects, but the evidence base remains smaller than the evidence for unipolar treatment-resistant depression.
Treatment also requires careful attention to mood stabilization and the possibility of hypomania or mania.
The important question is not simply whether ketamine works for depression. Clinicians also need to understand what type of depression they are treating and build the treatment plan around the correct diagnosis.
No. IV ketamine is not FDA approved for bipolar depression. Its psychiatric use in this setting is off-label.
Hypomanic and manic symptoms have been reported during ketamine treatment, although the precise risk is uncertain because studies in bipolar depression remain relatively small. Patients should be appropriately screened and monitored.
Published IV ketamine studies in bipolar depression have generally administered ketamine alongside ongoing mood-stabilizing treatment. Medication changes should be individualized and directed by the treating clinicians.
